CN104768573B - 用于位点特异性uPAR靶向的177‑Lu标记肽 - Google Patents
用于位点特异性uPAR靶向的177‑Lu标记肽 Download PDFInfo
- Publication number
- CN104768573B CN104768573B CN201380032450.2A CN201380032450A CN104768573B CN 104768573 B CN104768573 B CN 104768573B CN 201380032450 A CN201380032450 A CN 201380032450A CN 104768573 B CN104768573 B CN 104768573B
- Authority
- CN
- China
- Prior art keywords
- upar
- dota
- peptide
- cancer
- pet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6456—Plasminogen activators
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (2)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA201200321 | 2012-05-08 | ||
DKPA201200321 | 2012-05-08 | ||
PCT/DK2013/050126 WO2013167130A1 (en) | 2012-05-08 | 2013-05-03 | 177-Lu LABELED PEPTIDE FOR SITE-SPECIFIC uPAR-TARGETING |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104768573A CN104768573A (zh) | 2015-07-08 |
CN104768573B true CN104768573B (zh) | 2017-08-29 |
Family
ID=49550163
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201380032450.2A Active CN104768573B (zh) | 2012-05-08 | 2013-05-03 | 用于位点特异性uPAR靶向的177‑Lu标记肽 |
Country Status (7)
Country | Link |
---|---|
US (2) | US10994032B2 (zh) |
EP (1) | EP2846826B1 (zh) |
JP (2) | JP2015532636A (zh) |
CN (1) | CN104768573B (zh) |
CA (1) | CA2905172C (zh) |
HK (1) | HK1212219A1 (zh) |
WO (1) | WO2013167130A1 (zh) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015532636A (ja) * | 2012-05-08 | 2015-11-12 | リグスホスピタレト | 部位特異的uPAR標的化のための177−Lu標識ペプチド |
CA3106713C (en) * | 2012-12-03 | 2024-01-09 | Curasight Aps | Positron emitting radionuclide labeled peptides for human upar pet imaging |
DK3193945T3 (da) | 2014-09-17 | 2020-11-16 | Fluoguide As | Upar-målrettende peptid til anvendelse ved peroperativ optisk billeddannelse af invasiv cancer |
WO2017192605A1 (en) * | 2016-05-02 | 2017-11-09 | University Of Pittsburgh -Of The Commonwealth System Of Higher Education | Dimerization strategies and compounds for molecular imaging and/or radioimmunotherapy |
RU2757768C2 (ru) * | 2016-08-19 | 2021-10-21 | ФУДЖИФИЛМ Тояма Кемикал Ко., Лтд. | Композиция, содержащая буфер |
US20190358351A1 (en) * | 2016-11-17 | 2019-11-28 | Minerva Imaging Aps | 177-lu labeled active site inhibited factor vii |
EP3773670A4 (en) * | 2018-04-05 | 2022-03-09 | Tarveda Therapeutics, Inc. | CONJUGATES TARGETING HSP90 AND RELATED FORMULATIONS |
US10596276B2 (en) | 2018-07-25 | 2020-03-24 | Advanced Accelerator Applications (Italy) S.R.L. | Stable, concentrated radionuclide complex solutions |
US10596278B2 (en) | 2018-07-25 | 2020-03-24 | Advanced Accelerator Applications (Italy) S.R.L. | Stable, concentrated radionuclide complex solutions |
CN117412777A (zh) | 2020-12-01 | 2024-01-16 | 库拉赛特股份公司 | 尿激酶纤溶酶原活化剂受体靶向的放射性标记的肽缀合物 |
WO2023173074A2 (en) * | 2022-03-10 | 2023-09-14 | The Research Foundation For The State University Of New York | Immunostimulant-cytotoxic conjugate composition and methods for cancer treatment |
CN114874308B (zh) * | 2022-05-26 | 2023-02-17 | 苏州大学 | 一种核素标记的抑制肽及其制备方法和应用 |
WO2024153756A1 (en) | 2023-01-18 | 2024-07-25 | Curasight A/S | Radionuclide labelled peptide conjugate for site-specific upar-targeting |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101065152A (zh) * | 2004-09-29 | 2007-10-31 | 通用电气医疗集团股份有限公司 | 靶向尿激酶纤溶酶原激活物受体的造影剂 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4444690A (en) | 1982-02-25 | 1984-04-24 | University Patents, Inc. | Technetium chelates |
US4479930A (en) | 1982-07-26 | 1984-10-30 | Trustees Of The University Of Massachusetts | Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product |
US5120526A (en) | 1985-01-14 | 1992-06-09 | Neorx Corporation | Method of producing metal radionuclide labeled proteins for diagnosis and therapy |
US4861869A (en) | 1986-05-29 | 1989-08-29 | Mallinckrodt, Inc. | Coupling agents for joining radionuclide metal ions with biologically useful proteins |
US4965392A (en) | 1987-03-26 | 1990-10-23 | Neorx Corporation | Chelating compounds for metal-radionuclide labeled proteins |
US5175257A (en) | 1989-12-29 | 1992-12-29 | Neorx Corporation | Radiolabeled proteins for diagnostic or therapeutic use |
US5310536A (en) | 1992-02-06 | 1994-05-10 | Mallinckrodt Medical, Inc. | Ligands for improving metal chelate formation kinetics |
US5830431A (en) | 1995-06-07 | 1998-11-03 | Mallinckrodt Medical, Inc. | Radiolabeled peptide compositions for site-specific targeting |
US5942492A (en) | 1996-11-12 | 1999-08-24 | Angstrom Pharmaceuticals, Inc. | Cyclic peptides that bind to urokinase-type plasminogen activator receptor |
US6277818B1 (en) * | 1998-10-29 | 2001-08-21 | Angstrom Pharmaceuticals, Inc. | Cyclic peptide ligands that target urokinase plasminogen activator receptor |
AR020101A1 (es) | 1998-07-01 | 2002-04-10 | Cancerforskingsfonden Af 1989 | Un antagonista peptido del receptor de uroquinasa humana, composicion farmaceutica que lo contiene, su uso para la manufactura de un medicamento y metodopara seleccionar un antagonista peptido adecuado. |
AU780730B2 (en) | 1999-10-01 | 2005-04-14 | Angstrom Pharmaceuticals, Inc. | Diagnostic probes and therapeutics targeting uPA and uPAR |
US20070190068A1 (en) * | 2005-10-10 | 2007-08-16 | Richard Hart | uPAR-binding molecule-drug conjugates and uses thereof |
WO2007134274A2 (en) * | 2006-05-12 | 2007-11-22 | Attenuon, Llc | Antibodies to urokinase- type plasminogen activator receptor(upar)bind cancer stem cells: use in diagnosis and therapy |
HUE044625T2 (hu) * | 2011-08-31 | 2019-11-28 | Somscan Aps | PET nyomjelzõ neuroendokrin tumorok képalkotásához |
JP2015532636A (ja) * | 2012-05-08 | 2015-11-12 | リグスホスピタレト | 部位特異的uPAR標的化のための177−Lu標識ペプチド |
CA3106713C (en) * | 2012-12-03 | 2024-01-09 | Curasight Aps | Positron emitting radionuclide labeled peptides for human upar pet imaging |
DK3193945T3 (da) * | 2014-09-17 | 2020-11-16 | Fluoguide As | Upar-målrettende peptid til anvendelse ved peroperativ optisk billeddannelse af invasiv cancer |
-
2013
- 2013-05-03 JP JP2015510647A patent/JP2015532636A/ja active Pending
- 2013-05-03 WO PCT/DK2013/050126 patent/WO2013167130A1/en active Application Filing
- 2013-05-03 US US14/399,820 patent/US10994032B2/en active Active
- 2013-05-03 EP EP13788361.7A patent/EP2846826B1/en active Active
- 2013-05-03 CN CN201380032450.2A patent/CN104768573B/zh active Active
- 2013-05-03 CA CA2905172A patent/CA2905172C/en active Active
-
2016
- 2016-01-07 HK HK16100118.9A patent/HK1212219A1/zh unknown
-
2019
- 2019-01-17 JP JP2019005811A patent/JP6814234B2/ja active Active
-
2021
- 2021-01-07 US US17/144,067 patent/US20210236666A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101065152A (zh) * | 2004-09-29 | 2007-10-31 | 通用电气医疗集团股份有限公司 | 靶向尿激酶纤溶酶原激活物受体的造影剂 |
Non-Patent Citations (1)
Title |
---|
Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in a-emitter therapy for disseminated ovarian cancer;Knor S et al.;《Eur j nucl med mol imaging》;20070922;第35卷(第1期);摘要,讨论,图1 * |
Also Published As
Publication number | Publication date |
---|---|
CA2905172A1 (en) | 2013-11-14 |
EP2846826B1 (en) | 2018-07-25 |
EP2846826A4 (en) | 2015-12-23 |
US20150132219A1 (en) | 2015-05-14 |
EP2846826A1 (en) | 2015-03-18 |
US10994032B2 (en) | 2021-05-04 |
WO2013167130A1 (en) | 2013-11-14 |
JP2015532636A (ja) | 2015-11-12 |
CN104768573A (zh) | 2015-07-08 |
US20210236666A1 (en) | 2021-08-05 |
JP6814234B2 (ja) | 2021-01-13 |
HK1212219A1 (zh) | 2016-06-10 |
JP2019077712A (ja) | 2019-05-23 |
CA2905172C (en) | 2021-07-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104768573B (zh) | 用于位点特异性uPAR靶向的177‑Lu标记肽 | |
Shi et al. | Radiolabeled cyclic RGD peptides as radiotracers for tumor imaging | |
Jackson et al. | Clinical applications of radiolabeled peptides for PET | |
Banerjee et al. | 68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer | |
Li et al. | Functionally versatile and highly stable chelator for 111In and 177Lu: Proof-of-principle prostate-specific membrane antigen targeting | |
Chakraborty et al. | Evaluation of 111In-labeled cyclic RGD peptides: tetrameric not tetravalent | |
Bandari et al. | Synthesis and biological evaluation of copper-64 radiolabeled [DUPA-6-Ahx-(NODAGA)-5-Ava-BBN (7-14) NH2], a novel bivalent targeting vector having affinity for two distinct biomarkers (GRPr/PSMA) of prostate cancer | |
Garrison et al. | Evaluation of the pharmacokinetic effects of various linking group using the 111In-DOTA-X-BBN (7− 14) NH2 structural paradigm in a prostate cancer model | |
Liu et al. | Development of RGD-based radiotracers for tumor imaging and therapy: translating from bench to bedside | |
Lu et al. | A dual reporter iodinated labeling reagent for cancer positron emission tomography imaging and fluorescence-guided surgery | |
Sengupta et al. | Comparison of prostate‐specific membrane antigen ligands in clinical translation research for diagnosis of prostate cancer | |
Guo et al. | Metastatic melanoma imaging with an 111In-labeled lactam bridge-cyclized α-melanocyte-stimulating hormone peptide | |
Ho et al. | Molecular Imaging, Pharmacokinetics, and Dosimetry of 111In‐AMBA in Human Prostate Tumor‐Bearing Mice | |
Ogawa et al. | 68Ga-and 211At-Labeled RGD peptides for radiotheranostics with multiradionuclides | |
Cyr et al. | Somatostatin receptor-binding peptides suitable for tumor radiotherapy with Re-188 or Re-186. Chemistry and initial biological studies | |
Gao et al. | Improved in vivo targeting capability and pharmacokinetics of 99mTc-Labeled isoDGR by dimerization and albumin-binding for glioma imaging | |
Mosayebnia et al. | Design, synthesis, radiolabeling and biological evaluation of new urea-based peptides targeting prostate specific membrane antigen | |
Ui et al. | Development and characterization of a 68Ga-labeled A20FMDV2 peptide probe for the PET imaging of αvβ6 integrin-positive pancreatic ductal adenocarcinoma | |
Levashova et al. | Direct site-specific labeling of the Cys-tag moiety in scVEGF with technetium 99m | |
Yap et al. | Synthesis of a porphyrin with histidine-like chelate: an efficient path towards molecular PDT/SPECT theranostics | |
Cui et al. | Evaluation of 188Re-MAG2-RGD-bombesin for potential prostate cancer therapy | |
Holland et al. | Copper-64 radiopharmaceuticals for oncologic imaging | |
Qin et al. | In vivo near-infrared fluorescence and SPECT-CT imaging of colorectal Cancer using the bradykinin B2R-specific ligand icatibant | |
Zhao et al. | A novel 99mTc-labeled molecular probe for tumor angiogenesis imaging in hepatoma xenografts model: a pilot study | |
Zhao et al. | An integrin-αvβ6/α5β1-bitargeted probe for the SPECT imaging of pancreatic adenocarcinoma in preclinical and primary clinical studies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
EXSB | Decision made by sipo to initiate substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1212219 Country of ref document: HK |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20170717 Address after: Copenhagen Applicant after: TRT Innovations Ltd Address before: Copenhagen Applicant before: National Hospital |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1212219 Country of ref document: HK |